Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab versus cetuximab with mFOLFOX6 or FOLFIRI in first-line left-sided RAS/BRAF wild-type metastatic colorectal cancer
ISRCTN11118663Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Amivantamab and mFOLFOX6 or FOLFIRI with Cetuximab and mFOLFOX6 or FOLFIRI (2 arms). Primary endpoint: Progression-free survival. Started Oct 2024; status: recruiting.
02
Drugs
amivantamabcetuximabmFOLFOX6FOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN11118663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11118663.